ENEA Tech e Biomedical
VC Fund
Rome, Italy
ENEA Tech e Biomedical is a private foundation. It seeks to encourage the strengthening of research, development, and industrial reconversion of the biomedical sector.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 92%
Last updated:
For AI agents: llms.txt
Industries ENEA Tech e Biomedical invests in
Stages ENEA Tech e Biomedical invests in
Countries ENEA Tech e Biomedical invests in
Round sizes
Round size
- Series A
- $3.3M–$7.7M
- Venture - Series Unknown
- $530k–$21M
Investment Focus
Industry
- Health Care 9 (69%)
- Biotechnology 6 (46%)
- Medical Device 6 (46%)
- Medical 3 (23%)
- Therapeutics 3 (23%)
Stage
- Venture - Series Unknown 7 (54%)
- Series A 3 (23%)
- Grant 1 (8%)
- Series B 1 (8%)
- Post-IPO Debt 1 (8%)
Country
- Italy 12 (92%)
- Finland 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CellPly
|
Cellply is a life-science company focused on developing next-generation analytical tools enabling a deep characterization of cancer immunotherapies, cell therapies and cell-based biotherapeutics. The company aims to support the development of novel cancer immunotherapies by accelerating R&D, automating the quality control and advancing theability to monitor the clinical response to these treatments.Through the use of proprietary microfluidic technologies with Co-Culture Array technology, highly-automated analytical instruments and AI-powered image and data analytics, Cellply products define the function of the immune system one cell at a time, combining functional data with other multiplex data and providing unprecedented single-cell analytical solutions. | $8.4M / Venture - Series Unknown / Apr 23, 2026 | |
Recornea
|
Recornea is a developer of a corneal medical device to restore the physiological curvature of the cornea with clear and predictable clinical outcomes. | $529.8K / Venture - Series Unknown / Jul 23, 2025 | |
Health Triage
|
Health Triage researches, designs, and develops clinical data, new technologies, and applications for the health sector. Their research activities focus on the development of new screening protocols and innovative diagnosis processes, exploiting deep learning to facilitate the acquisition of new technologies through data learned from algorithms andneural networks. | $5M / Venture - Series Unknown / May 21, 2025 | |
Biovitae
|
Biovitae focuses on patent development in infection control and prevention, aiming to translate scientific discoveries into practical applications for human health and quality of life. | $5.7M / Series A / Apr 22, 2025 | |
Iama Therapeutics
|
At IAMA Therapeutics, we are constantly pushing the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of children suffering from brain disorders and their families. Our purpose is to provide a therapeutic solution to children suffering from neurological conditions and provide their families withthe support they need. | $17.1M / Venture - Series Unknown / Apr 16, 2025 | |
VR Media Srl
|
In today’s industrial mature market , service revenue have is as or more important that the revenues from first sales. This is due to higher competition leading to reduced machinery margin, to the higher and higher productivity Customers demand from their equipment, combined with growing technological complexity and less and less skilled labouravailable to reside in remote or hazardous enironments. No need to say, in this scenario service costs are significant, and growing. This is the perfect set up for the application of virtual reality technology, and the ability to virtually displace in real time the know how and competence of few highly competent experts through the eyes, ears and hands of better distributed/local generalist technicians. VR Media, with its unique turn key technology, has developed a very efficient and and cyber-safe solution for its Partner Customers. Special value is for those companies that have to maintain high tech machinery in remote or hazardous sites. | $5.5M / Venture - Series Unknown / Apr 03, 2025 | |
Genenta Science
|
Genenta Science is a biotechnology company that develops gene transfer therapy for the treatment of cancer tumors. The company is based in Milan, Italy. | $21.8M / Post-IPO Debt / Mar 19, 2025 | |
Valo Therapeutics
|
Valo Therapeutics is an immunotherapy company that is developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The Valo Tx platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. It turns oncolytic adenovirusesinto targeted tissue specific cancer vaccines without the need to generate and manufacture multiple genetically modified viruses. The company is also developing PeptiENV, among other neoantigen strategies, in collaboration with Professor Cerullo. PeptiENV is expected to improve the therapeutic response to enveloped oncolytic viruses in the treatment of multiple forms of cancer. | $20.6M / Venture - Series Unknown / Mar 10, 2025 | |
Approxima
|
Approxima is an early-stage MedTech startup that is creating a percutaneous tricuspid valve replacement method. The company is demonstrating in vivo safety, efficacy, and feasibility through preclinical feasibility phase trials. | $7.7M / Series A / Feb 20, 2025 | |
Newronika
|
Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies. | $14.2M / Series B / Feb 13, 2025 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does ENEA Tech e Biomedical invest in?
ENEA Tech e Biomedical invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Venture - Series Unknown and Series A stage. Most of the 13 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is ENEA Tech e Biomedical's check size?
ENEA Tech e Biomedical typically joins rounds of $3.3M–$7.7M at Series A and $530k–$21M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ENEA Tech e Biomedical participates in.
When did ENEA Tech e Biomedical last invest?
The most recent investment recorded for ENEA Tech e Biomedical closed in Apr 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
